Last reviewed · How we verify
Lactulose oral solution treatment
At a glance
| Generic name | Lactulose oral solution treatment |
|---|---|
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of the Outcome of Fecal Microbiota Transplantation (PHASE1, PHASE2)
- Effect of Lactobacillus DSM17938+ on Functional Constipation and Intestinal Flora in Pregnant Women (NA)
- Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose (PHASE4)
- Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment (PHASE1)
- Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy (PHASE4)
- Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability (EARLY_PHASE1)
- OCR002-SP103 - Oral Immediate Release Study (PHASE1)
- To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: